SeaCrest Wealth Management’s Abiomed Inc ABMD Stock Holding History

SeaCrest Wealth Management’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-730	Closed	-$181K	–	1627
2022 Q2	$181K	Buy	730 +40	+6%	+$10.8K	0.02%	644
2022 Q1	$229K	Buy	690 +40	+6%	+$12.3K	0.03%	611
2021 Q4	$233K	Hold	650	–	–	0.03%	598
2021 Q3	$212K	Hold	650	–	–	0.03%	612
2021 Q2	$203K	Sell	650 -13	-2%	-$3.99K	0.02%	645
2021 Q1	$211K	Sell	663 -7	-1%	-$2.24K	0.03%	596
2020 Q4	$217K	Buy	+670	New	+$185K	0.03%	543
2019 Q2	–	Sell	-555	Closed	-$159K	–	2009
2019 Q1	$159K	Hold	555	–	–	0.03%	539
2018 Q4	$180K	Sell	555 -123	-18%	-$42.7K	0.04%	452
2018 Q3	$305K	Sell	678 -247	-27%	-$97.4K	0.05%	385
2018 Q2	$378K	Sell	925 -50	-5%	-$18.1K	0.07%	315
2018 Q1	$284K	Hold	975	–	–	0.05%	380
2017 Q4	$183K	Buy	+975	New	+$182K	0.03%	525

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

SeaCrest Wealth Management's ABMD Position: Q3 2022 in Review

SeaCrest Wealth Management sold out of Abiomed Inc (ABMD) in Q3 2022, closing a stake of 730 shares — an estimated $181K sold.

SeaCrest Wealth Management first reported a position in ABMD in Q4 2017 and held it in 13 quarters. The position peaked at $378K in Q2 2018. 517 funds tracked by Wall St. Rank hold ABMD as of Q3 2022.

SeaCrest Wealth Management reported no remaining Abiomed Inc position as of Q3 2022 after selling out during the quarter.
SeaCrest Wealth Management sold 730 Abiomed Inc shares in Q3 2022, an estimated $181K.
SeaCrest Wealth Management first reported a position in Abiomed Inc in Q4 2017 and held it in 13 quarters.
SeaCrest Wealth Management's Abiomed Inc position peaked at $378K in Q2 2018.
517 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2022.

Based on SeaCrest Wealth Management's 13F filing for Q3 2022, filed 15 Nov 2022.